Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, Propagation and removal of cerebral amyloid angiopathy, and much more.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. xiii 6. Preface - p. xvii 7. Section I: Targetting AD - p. xvii 8. Chapter One: Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings - p. xvii 9. Chapter Two: Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis - p. 23 10. Chapter Three: Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid β-protein - p. 55 11. Section II: Etiology of AD - p. 67 12. Chapter Four: In search of pathogenic amyloid β-peptide in familial Alzheimer's disease - p. 67 13. Chapter Five: Biology of splicing in Alzheimer's disease research - p. 78 14. Chapter Six: Acquired cerebral amyloid angiopathy: An emerging concept - p. 84 15. Section III: Neuroimmunology of AD - p. 95 16. Chapter Seven: Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease - p. 95 17. Chapter Eight: Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease - p. 145 18. Chapter Nine: Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges? - p. 181 19. Section IV: AD therapy - p. 201 20. Chapter Ten: Alzheimer's therapy development: A few points to consider - p. 201 21. Chapter Eleven: The next steps in curing Alzheimer's disease - p. 217 22. Chapter Twelve: Future horizons in Alzheimer's disease research - p. 221 23. Chapter Thirteen: Why delay in effective treatment for Alzheimer's disease and related conditions - p. 241 24. Chapter Fourteen: Restoring synaptic function through multimodal therapeutics - p. 256 25. Chapter Fifteen: Disease-modifying therapy for proteinopathies: Can the exception become the rule? - p. 275 26. Chapter Sixteen: Combination therapy for Alzheimer's disease and related dementias - p. 287 27. Section V: Alpha-synucleinopathies - p. 296 28. Chapter Seventeen: Can infections trigger alpha-synucleinopathies? - p. 296 29. Chapter Eighteen: Prion-like propagation of α-synuclein in neurodegenerative diseases - p. 322 30. Section VI: Model systems - p. 348 31. Chapter Nineteen: Yeast models of neurodegenerative diseases - p. 348 32. Index - p. 381
Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, Propagation and removal of cerebral amyloid angiopathy, and much more.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Contributors - p. xiii 6. Preface - p. xvii 7. Section I: Targetting AD - p. xvii 8. Chapter One: Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings - p. xvii 9. Chapter Two: Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis - p. 23 10. Chapter Three: Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid β-protein - p. 55 11. Section II: Etiology of AD - p. 67 12. Chapter Four: In search of pathogenic amyloid β-peptide in familial Alzheimer's disease - p. 67 13. Chapter Five: Biology of splicing in Alzheimer's disease research - p. 78 14. Chapter Six: Acquired cerebral amyloid angiopathy: An emerging concept - p. 84 15. Section III: Neuroimmunology of AD - p. 95 16. Chapter Seven: Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease - p. 95 17. Chapter Eight: Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease - p. 145 18. Chapter Nine: Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges? - p. 181 19. Section IV: AD therapy - p. 201 20. Chapter Ten: Alzheimer's therapy development: A few points to consider - p. 201 21. Chapter Eleven: The next steps in curing Alzheimer's disease - p. 217 22. Chapter Twelve: Future horizons in Alzheimer's disease research - p. 221 23. Chapter Thirteen: Why delay in effective treatment for Alzheimer's disease and related conditions - p. 241 24. Chapter Fourteen: Restoring synaptic function through multimodal therapeutics - p. 256 25. Chapter Fifteen: Disease-modifying therapy for proteinopathies: Can the exception become the rule? - p. 275 26. Chapter Sixteen: Combination therapy for Alzheimer's disease and related dementias - p. 287 27. Section V: Alpha-synucleinopathies - p. 296 28. Chapter Seventeen: Can infections trigger alpha-synucleinopathies? - p. 296 29. Chapter Eighteen: Prion-like propagation of α-synuclein in neurodegenerative diseases - p. 322 30. Section VI: Model systems - p. 348 31. Chapter Nineteen: Yeast models of neurodegenerative diseases - p. 348 32. Index - p. 381
